EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

DIGITAL CONTENT

7 NEWS #PharmaBuzz

media
7 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Lxh254, 1800398-38-2, Lxh-254, Lxh254 free base, N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, Pan-raf inhibitor lxh254

Molecular Formula

C₂₅H₂₅F₃N₄O₄

Molecular Weight

502.5 g/mol

InChI Key

UEPXBTCUIIGYCY-UHFFFAOYSA-N

FDA UNII

15JL80DG6H

Naporafenib is an orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.

1 2D Structure

Naporafenib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide

2.1.2 InChI

InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)

2.1.3 InChI Key

UEPXBTCUIIGYCY-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C=C(C=C1)NC(=O)C2=CC(=NC=C2)C(F)(F)F)C3=CC(=NC(=C3)OCCO)N4CCOCC4

2.2 Other Identifiers

2.2.1 UNII

15JL80DG6H

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Lxh254

2.3.2 Depositor-Supplied Synonyms

1. Lxh254

2. 1800398-38-2

3. Lxh-254

4. Lxh254 Free Base

5. N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

6. Pan-raf Inhibitor Lxh254

7. Naporafenib [inn]

8. 15jl80dg6h

9. 1800398-38-2 (free Base)

10. N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide

11. 4-pyridinecarboxamide, N-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)-

12. N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) Pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamide

13. N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide

14. Lxh 254

15. K81

16. Unii-15jl80dg6h

17. Naporafenib [who-dd]

18. Chembl4583691

19. Lxh 254 [who-dd]

20. Schembl16094629

21. Bdbm88120

22. Gtpl10658

23. Bcp29080

24. Ex-a1846

25. Nsc807047

26. S8745

27. Akos037648965

28. At23218

29. Nsc-807047

30. Compound 15 [pmid: 31059256]

31. Ac-36207

32. Bl166445

33. Bs-16133

34. Hy-112089

35. Cs-0043317

36. Example 1156 [wo2014151616a1]

37. A16841

38. Us9694016, 1156

2.4 Create Date

2015-02-13

3 Chemical and Physical Properties

Molecular Formula	C₂₅H₂₅F₃N₄O₄
Molecular Weight	502.5 g/mol
XLogP3	3.2
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	7
Exact Mass	502.18278978 g/mol
Monoisotopic Mass	502.18278978 g/mol
Topological Polar Surface Area	96.8 Å²
Heavy Atom Count	36
Formal Charge	0
Complexity	709
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Naporafenib manufacturers, exporters & distributors on PharmaCompass

Naporafenib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

7 Drugs in Development

DIGITAL CONTENT

7 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?